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Introduction: Platelet hyper-reactivity, despite a standard anti-thrombotic therapy,
is a recognized risk factor for recurrent myocardial ischemia and in-stent thrombosis
following PCI. We have investigated whether this detrimental condition, measured by
collagen–epinephrine closure times (CEPI-CT) with the Platelet Function Analyzer
(PFA-100) device could predict IST defined as the composite of cardiovascular death
or myocardial infarction.
Materials and methods: CEPI-CT was measured in 256 consecutive patients with
stable angina (n=103) or ACS (n=153) 30±8 h after PCI (T0) and 1 month later (T1). All
patients were followed up for a mean period of 9 months. Platelet hyperactivity was
defined as a CEPI-CTb190 s.
Results: Baseline CEPI-CTb190 s was associated with a higher rate of death or MI
(LogRank χ2=4.23, p=0.039) as compared with CEPI-CTN190 s (4.6% vs. 0.7%).
Multivariable analysis after adjustment for other risk factors confirmed that baseline
CEPI-CTb190 s was an independent correlate for death or MI (Hazard ratio 6.981,
p=0.008). At T1 there was a significant prolongation of CEPI-CT (p=0.03) from 208±
64 s to 240±59 s but T1 did not predict any event.KEYWORDS
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408 G. Jacopo et al.Conclusions: A CEPI-CTb190 s measured within the first 24 h following PCI predicts
IST defined as the occurrence of death or MI.
© 2007 Elsevier Ltd. All right reserved.Introduction
In-stent thrombosis (IST) is a dramatic and mostly
unpredictable complication affecting, in the real
world, around 3% of otherwise successful PCI [1].
New generation drug eluting stents (DES) are related
to a potentially higher risk of IST, due to the late
process of endothelialization [2]. Platelet hyper-
reactivity, which is a powerful risk factor for
recurrent myocardial ischemia in patients under-
going PCI, is strongly implicated in the pathophysiol-
ogy of IST [3]. Point-of-care tests have been deve-
loped in an attempt to more easily measure platelet
function and to monitor the effects of antiplatelet
therapy. Platelet Function Analyzer-100 (PFA-100) is
a rapid and reproducible test allowing a quantitative
measurement of platelet function. It has been shown
to be sensitive to aspirin response [4,5] but also to
predict subsequent coronary events following PCI
[6]. In the present study, we hypothesized that
platelet function assessment with the PFA-100 POC
assay immediately after PCI was an independent
predictor of IST. For that purpose, we performed a
prospective study of patients who underwent PCI
and measured platelet function using the POCT PFA-
100 immediately and 1 month after PCI. All patients
were followed up for 9 months.Methods
Study design
The study protocol was approved by the local Ethical
Committee and informed consent was obtained from
all subjects (n=256) who entered the study after
successful PCI. A total of 153 patients underwent PCI
in the context of an evolving STEMI (n=47) or within
48 h of admission for NSTEMI (n=106). The remaining
patients underwent PCI for stable angina (Table 1).
All the patients underwent platelet function evalua-
tionwithin an average of 30±8 h after PCI and at least
more than 24 h after the interruption of IIb/IIIa
receptor antagonists (Tirofiban) (T0) and 1 month
later (T1): at T0 we identified early poor responders
to antiplatelet therapy, whereas at T1 we verified the
compliance to therapy. A cut-off value of 190 s was
chosen to define platelet hyperactivity because it has
been shown to identify aspirin non-responders at riskfor subsequent acute coronary events [7–9]. A p
value less than 0.05 is indicated as significant. All the
patients received a dual oral antiplatelet regimen
(aspirin and thienopyridine) for a planned 6-month
period. Clopidogrel was given in the majority of
patients (92%), as a loading dose of 300 mg followed
by a maintenance dose of 75mg/day. Ticlopidine was
given in the remaining 8% of the patients, at the dose
of 500 mg/day. IIb/IIIa receptor antagonists were
used in 84 patients with NSTEMI with positive
Troponin I before PCI. Assuming from previous data
[6] an event rate (death or MI) of 5% in the CEPI-
CTb190 s and 1% in the CEPI-CTN190 s, the number of
patients planned to provide the studywith 80% power
with a type I error rate equal to 5% was calculated to
be 250.
Blood collection
Blood samples for analysis of platelet function were
collected into evacuated tubes (Vacutainer, Becton
Dickinson) containing 3.8% citrate. Platelet function
was evaluated using the Platelet Function Analyzer-
100 (PFA-100; Dade Behring) which provides a
quantitative measure of primary platelet-related
hemostasis at high shear stress [10]. It is a rapid,
simple, and reproducible test. A total of 0.8 ml of
citrated whole blood is transferred into the reservoir
of a disposable test cartridge within 4 h of blood
sampling. The anticoagulated blood is warmed to
37 °C and drawn under vacuum through a 200-μm-
diameter stainless steel capillary (thatmimics a small
or stenotic blood vessel) and a 150-μm-diameter
aperture in a nitrocellulose membrane coated with
collagen and epinephrine (CEPI). In response to the
high shear rates of 5000–6000 s−1 and the agonists, a
platelet aggregate forms that blocks blood flow
through the aperture; the time taken to occlude
the aperture is reported as the closure time and is
measured to a maximum of 300 s [11]. All measure-
ments were done from 1 to 4 h after blood sampling.
The reference range in normal subjects was 76–184″.
Coefficients of variation for duplicate analysis
averaged 15% with a day-to-day variability that was
around 10% for both cartridges, as elsewhere
reported [12]. It has also been used for monitoring
GpIIb/IIIa antagonists in patients undergoing percu-
taneous transluminal coronary angioplasty [13] and
for identifying of aspirin resistance [8].
Table 1 Demographics and clinical characteristics of patients recruited
Total CEPI-CTb190 s CEPI-CTN190 s P value
Number 256 109 147
Male sex (%) 60 62 58 0.62
Medical history, laboratory and instrumental data
Diabetes mellitus (%) 26 28 23 0.34
Hypertension (%) 32 29 33 0.46
Smoking habitus (%) 38 42 35 0.42
Hypercholesterolemia (%) 41 45 38 0.51
Diagnosis at admission
Acute coronary syndromes (%) 60 62 58 0.79
Medications during follow-up (intention-to-treat)
Aspirin, low dose b160 mg/die (%) 79 75 83 0.73
Aspirin, high dose N160 mg/die (%) 21 26 17 0.66
Thienopyridines (%) 100 100 100 0.96
Warfarin (%) 2 2 2 0.96
Clinical events during 9-month follow-up
Intrastent thrombosis=composite of death/MI/TIMI 0–1 (%) 0.7 0.04
Re-hospitalization for coronary restenosis (%) 3.9 6.4 2 0.06
Total coronary events 10.1 17.3 4.8 0.01
Major bleedings (%) 1.6 1.8 1.4 0.75
Hemodynamic findings and data
Coronary artery disease (mean±SD) 1.68±0.7 1.58±0.7 1.65±0.6 0.66
Number of treated vessels (mean±SD) 1.36±0.5 1.26±0.5 1.37±0.6 0.54
Cumulative length (mm) of stents implanted (mean±SD) 38±20 40±20 37±16 0.73
Percentage of medicated stents 47 48 46 0.79
In-hospital adjuvant therapy
GpIIb/IIIa antagonists (%) 30 32 28 0.85
Fibrinolytic therapy (%) 4 4 4 0.96
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Patients' follow-up was obtained by phone interview
for a mean period of 9±0.3 months. Non-invasive
identification of residual myocardial ischemia was
performed by treadmill at 3 and 6 months after PCI.
A coronary angiography was repeated in patients
with symptomatic ischemia or residual ischemia.
Objectives
The primary end-point was defined as the composite
of death or MI or by a thrombolysis in myocardial
infarction (TIMI) flow 0 or 1 by angiography at the
site of stent implantation. Residual ischemia and
target lesion revascularizations were considered as
secondary end-points.
Statistics
Comparisons among continuous variables were per-
formed by unpaired Student's t test, whereas
nominal variables were compared by the Chi-squared test (Statview 5.0.1, SAS Institute). Regres-
sions among continuous variables were calculated by
means of simple or multiple (step-wise) regression
analysis. Spearman's correlation coefficient was
used to test correlation among non-continuous
variables. Cumulative survival free of events during
follow-up was calculated by means of a Kaplan–
Meier analysis (Statview 5.0.1, SAS Institute). The
excess of risk related to parametric variables was
calculated by a Cox regression. All odds ratio are
given with their 95% confidence interval (CI).
Results
Patients characteristics
Demographic and clinical data at the time of
recruitment are presented in Table 1. Our popula-
tion included 256 unselected coronary patients:
40.5% stable angina, 18.3% STEMI, 41.2% NSTEMI at
low to intermediate risk. Cardiogenic shock and
Figure 2 Kaplan–Meier cumulative survival free of MACE,
LogRank χ2=6.981, p=0.008.
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(43%) showed a CEPI-CTb190 s. There were no
significant differences between the two groups of
patients (CEPI-CT b or N190 s) regarding both
clinical characteristics and procedural data.
Clinical end-points
A total of 18 events were identified during FU
including 6 IST (primary end-point). Five patients
had a subacute IST (during the first 4 weeks following
PCI) and 1 had a late IST. The IST-free survival for the
patients with CEPI-CTb190 s was 95.4% compared
with 99.3% for the patients with CEPI-CTN190 s. The
cumulative survival free of IST based on Kaplan–
Meier analysis is reported in Fig. 1 (LogRank χ2 =4.23,
p=0.039). Three of the 5 subacute IST occurred
during the first week, whereas the late IST occurred
within 4 months of the procedure. Of note, the case
of late IST was associated with a spontaneous
interruption of the clopidogrel assumption, despite
the standard indication given by our center to
continue the dual antiplatelet therapy for the first
6 months following PCI.
At 9-month follow-up the overall event-free
survival for the patients with CEPI-CTb190 s was
83.6% compared with 96.4% for the patients with
CEPI-CTN190 s. The cumulative survival free of total
coronary events based on Kaplan–Meier analysis is
reported in Fig. 2 (LogRank χ2 =6.981, p=0.008).
In Fig. 3 is reported the cumulative survival free of
stable angina/ischemia with an angiographic doc-
umentation of coronary restenosis: 7 of 10 patients
had a baseline CEPI-CTb190 s (LogRank χ2 =3.401,
p=0.065).
CEPI-CT distribution at T0 and T1 is reported in
Fig. 4 (panels A and B): we observed a significant
prolongation of CEPI-CT (from 208±64 s to 240±59 s,
respectively, p=0.03), with a percentage of CEPI-
CTb190 s reduced from 43 to 25%. In panel C the
T0−T1 gradient is illustrated, with a mean value of
+35±57 s.Figure 1 Kaplan–Meier cumulative survival free of IST,
LogRank χ2=4.236, p=0.039.Independent predictors of IST
Univariate and multivariate analysis by Cox model
of regression showed that variables associated with
a significant hazard risk for IST were bifurcation
lesions and CEPI-CTb190 s at T0 (Table 2).Discussion
Our study provides the first evidence that identifi-
cation of post-PCI platelet hyper-reactivity using
the PFA-100 POCT can predict IST.
Identification of high ADP-induced platelet activ-
ity using standard optical aggregometry and the
VASP test has been shown to correlate with the risk
of IST [3]. In the present study, we demonstrate that
a POCT test for platelet function, with the
advantage of easy reproducibility, is also relevant
and reliable. Moreover, although the CEPI-CT by
PFA-100 is poorly sensitive to the effect of clopido-
grel alone, it is quite sensitive to the effect of dual
antiplatelet therapy, aspirin plus a thienopyridine,
with an all-or-none modality of response that can be
convenient to assess the global effect of combined
antiplatelet regimen [14].
Our findings further emphasize the pathophysio-
logic relationship between the platelet activationFigure 3 Kaplan–Meier cumulative survival free of stable
ischemia/angina, LogRank χ2=3.401, p=0.06.
Table 2 Results of time-to-event analysis by Cox
model of regression
Univariate HR (95% CI) P value
Age 1.03 (0.98–1.05) 0.84
Diabetes 1.97 (0.41–5.93) 0.12
Smoking habitus 1.27 (0.34–4.73) 0.68
Hypertension 0.84 (0.4–1.76) 0.64
Cholesterol-LDL 0.81 (0.4–1.68) 0.57
CEPI-CTb190 s at
T0
4.95 (1.63–15.03) 0.01
CEPI-CTb190 s at
T1
1.71 (0.63–4.59) 0.28
CEPI-CT (T0−T1) 0.91 (0.42–1.78) 0.76
Biforcation lesions 12.23 (2.76–53.97) 0.001
Renal insufficiency 1.31 (0.603–2.89) 0.61
Ejection fraction 0.73 (0.168–3.178) 0.67
Results of multivariate time-to-event analysis by Cox
model of regression
Multivariate HR (95% CI) P value
Biforcation lesions 57.42 (7.98–412.82) 0.0001
CEPI-CTb190 s at
T0
9.74 (2.22–42.86) 0.002
Legend: CI=confidence interval; HR=hazard ratio; CEPI-CT=
collagen epinephrine closure time.
Figure 4 Distribution of the patients for CEPI-CT values, at
T0 (panel A) and T1 (panel B). In panel C the T0−T1 gradient is
illustrated.
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otherwise successful PCI, with an hypothetical
higher incidence in the era of DES [15,16].
The availability of POC tests in the evaluation of
platelet function, such as PFA-100, makes it possible
for the risk stratification of patients undergoing an
elective or urgent PCI with subsequent recurrent
acute coronary event or ISTand eventually to adapt
the standard anti-thrombotic therapy on the basis of
the individual risk profile.
The threshold of CEPI-CT (b or N190 s) we have
selected to define platelet hyperactivity is the oneaccepted to discriminate the state of aspirin
resistance [10,11].
We have already noted that patients with a CEPI-
CTb190 s after PCI are exposed to higher risk of
clinical recurrent events [6]; therefore, this value
maybe considered a plausible threshold to establish
whether a more aggressive anti-thrombotic strategy
is indicated. In our study the rate of baseline CEPI-
CTb190 s in patients with recurrent stable ischemia
due to coronary restenosis was higher but still not
statistically significant (p=0.06, Fig. 3) and this
result can be justified by the weaker relationship
between platelet activation and the process of
restenosis. Since most of the total coronary events
reported in Fig. 2 were secondary to stable
ischemia/angina, occurring after several weeks
from PCI, this makes reasonable the weaker
relationship with CEPI-CT at T1.
We also observed that the platelet activation state
is significantly time related: the longer the distance
from the acute phase post-PCI, the higher the
probability to observe a reduced platelet activation.
In fact, the rate of aspirin non-responder patients
decreased in about 30 days (44.2% vs. 24.8%). The
evaluation of the platelet activation state at T1 loses
most of its prognostic value, but itmay depend on the
very small number of late IST in our population (Table
2). Moreover, the role of PFA-100 in assessing the risk
of late IST remains open, since the only late event in
412 G. Jacopo et al.our population was due to the interruption of
clopidogrel. The significant prolongation of CEPI-CT
after 1 month can be justified by the relationship
between the peri-procedural inflammatory response
and the pro-thrombotic phenotype [17]: a higher
thrombin level may be the pathophysiological link
with the state of platelet activation. T1 measure-
ments were also performed to check the treatment
compliance, that was almost complete (98% at 30
days) in our population.
We recruited both acute and stable coronary
syndromes, similarly to large cohort studies focusing
on the incidence of IST, since the rate of IST after
coronary stent deposition is independent on the
clinical syndrome leading to PCI [16,17]. The
relatively higher rate of IST in our population
(2.3%) as compared with other larger registry [18]
can be explained by the relatively higher percentage
of bifurcation lesion. In fact, we confirmed that the
bifurcation lesion is the most powerful predictor of
IST, without abolishing the significance of CEPI-
CTb190 s at T0 in the multivariate model of
regression (Table 2). Recent observations report
the role of dual antiplatelet therapy interruption as
amajor risk factor for IST [18,19]: we also observed a
case of late IST in a patient who prematurely
interrupted clopidogrel assumption; however, we
also report a higher risk of IST in patients on standard
dual antiplatelet therapy, in case of persistent
platelet hyperactivity, as detected by PFA-100.
Conclusions
Even if these data are limited to a relatively small
number of cases and require a confirmation by
larger multicentric studies, the observation of the
significant predictive value of CEPI-CT for the risk of
IST suggests the opportunity to stratify the throm-
botic risk of patients undergoing PCI with a rapid
evaluation of platelet function by PFA-100. If
confirmed that PFA-100 may help to target poor
responders to dual antiplatelet therapy who might
need higher loading dose of clopidogrel, as recently
suggested by the ALBION study [20].
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